A Chapel Hill-based therapeutic development company filed to raise $900,000 in equity, according to a Securities and Exchange Commission filing.

Chaperone Therapeutics Inc. filed a Form D on Jan. 12, stating it has raised $456,569 of the total offering of $900,000. Proceeds will be used for working capital, which may include normal compensation to executive officers.

Privately held Chaperone Therapeutics is developing therapies for neurodegenerative and rare diseases caused by protein misfolding. The company’s approaches “elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death,” according to its website.

Chief Business and Operating Officer Maria Sippola-Thiele has been with Chaperone Therapeutics since 2009.

Sippola-Thiele graduated from a university in Finland with a doctorate of philosophy, biochemistry and molecular biology.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must first file what’s known as a Form D electronically with the SEC after they first sell their securities.